Related Experiment Videos
Overview of the management of pediatric heart failure
1Pediatric Cardiology Program, New York University Medical Center, 530 First Avenue, 10016, New York, NY, USA
Insights
Heart failure treatment has evolved from managing pump dysfunction to addressing complex biological disorders. Current strategies, like beta-blockers, target myocardial maladaptation for improved long-term outcomes in adults, with potential pediatric applications.
Area of Science:
- Cardiology
- Pharmacology
- Pediatric Cardiology
Background:
- Historically, heart failure was viewed as a pump failure issue with hemodynamic consequences.
- Therapies focused on improving cardiac output and circulatory conditions, yielding short-term symptom relief but not altering long-term prognosis.
- Pediatric heart failure presents unique challenges due to a lack of large-scale trials.
Purpose of the Study:
- To review the evolution of heart failure understanding and treatment strategies.
- To discuss current therapeutic targets, including biological disorders and myocardial maladaptation.
- To explore the potential extrapolation of adult treatment principles to pediatric populations.
Main Methods:
- Literature review of heart failure pathophysiology and treatment evolution.
- Analysis of traditional and contemporary therapeutic approaches.
- Discussion of the rationale for applying adult treatment paradigms to children.
Main Results:
- Heart failure is now recognized as a complex disorder involving multiple interactive pathophysiologic mechanisms.
- Contemporary treatments target not only hemodynamics but also biological pathways, aiming to reverse or slow myocardial maladaptation.
- Paradoxical therapies, such as beta-blockers, are now key components of heart failure management.
Conclusions:
- The understanding of heart failure has shifted from a simple pump failure model to a complex pathophysiologic syndrome.
- Modern pharmacologic strategies aim to address underlying biological abnormalities and improve the natural history of the disease.
- Evidence-based adult treatment principles may offer a framework for managing heart failure in children.
Abstract:
For the most part of this the century heart failure syndrome was understood as a pump failure disorder with hemodynamic consequences stemming from the same myocardial dysfunction. In addition supply and demand theories were used to explain the nature of symptoms. As a result, therapeutic strategies were directed at correcting the abnormal hemodynamic conditions and normalizing the delivery of the much needed nutrients. Improvement of cardiac pump function with inotropic drugs and abnormal circulatory conditions with afterload and preload modifications became therapeutic goals and standards of care. However, while vasodilators and inotropic drugs immediately improved symptoms, hemodynamics and functional status, in the long term they either did not affect or worsen the natural history of heart failure. In pediatrics, this is further complicated by the lack of large scale trials addressing issues pertinent to the particularities that affect heart failure in children. In the late 1980s and 1990s heart failure has evolved into a more complex, multiple and interactive pathophysiologic disorder. Today not only the abnormal hemodynamics but also the biological disorders are pharmacologic targets. The reversal or slowing of myocardial maladaptation has become one of the most important therapeutic goals. With this end in mind therapeutic strategies may seem counterintuitive and paradoxical, such as the use of beta-blockers. This review will address the current thinking and therapeutic modalities used today in the treatment of heart failure syndrome in the adult population. We also discuss some of the issues why we think that these principles can be extrapolated to the pediatric population.